본문 바로가기

Report

All 3,252,562 Page 77/325,257

검색
  • 2025


    • Book : 185()
    • Pub. Date : 2025
    • Page : pp.108957
    • Keyword :
  • 2025

    Abstract

    Tissue‐mimicking reference phantoms are indispensable for the development and optimization of magnetic resonance (MR) measurement sequences. Phantoms have greatest utility when they mimic the MR signals arising from tissue physiology; however, many of the properties underlying these signals, including tissue relaxation characteristics, can vary as a function of magnetic field strength. There has been renewed interest in magnetic resonance imaging (MRI) at field strengths less than 1 T, and phantoms developed for higher field strengths may not be physiologically relevant at these lower fields. This work focuses on developing materials with specific relaxation properties for lower magnetic field strengths. Specifically, we developed recipes that can be used to create synthetic samples for target nuclear magnetic resonance relaxation values for fields between 0.0065 and 0.55 T. and mixing models for agarose‐based gels doped with a paramagnetic salt (one of CuSO4, GdCl3, MnCl2, or NiCl2) were created using relaxation measurements of synthetic gel samples at 0.0065, 0.064, and 0.55 T. Measurements were evaluated for variability with respect to measurement repeatability and changing synthesis protocol or laboratory temperature. The mixing models were used to identify formulations of agarose and salt composition to approximately mimic the relaxation times of five neurological tissues (blood, cerebrospinal fluid, fat, gray matter, and white matter) at 0.0065, 0.0475, 0.05, 0.064, and 0.55 T. These mimic sample formulations were measured at each field strength. Of these samples, the GdCl3 and NiCl2 measurements were closest to the target tissue relaxation times. The GdCl3 or NiCl2 mixing model recipes are recommended for creating target relaxation samples below 0.55 T. This work can help development of MRI methods and applications for low‐field systems and applications.


    • Book : 38(1)
    • Pub. Date : 2025
    • Page : pp.e5281
    • Keyword :
  • 2025

    ABSTRACT

    Berberine, an isoquinoline alkaloid derived from various medicinal plants, emerges as a potential therapeutic agent against diverse human diseases. It has particularly shown notable anticancer efficacy against breast, colorectal, lung, prostate, and liver cancer. Berberine results in inhibition of cancer cell proliferation, induction of apoptosis, and suppressing angiogenesis, positioning it as a versatile, multitargeted therapeutic tool against cancer. Notably, berberine enhances the effectiveness of conventional chemotherapeutic drugs, mitigating associated drug resistance. Mechanistically, it has been shown to exert its efficacy by targeting molecules like nuclear factor‐kappa B (NF‐κB), mitogen‐activated protein kinases (MAPKs), and phosphoinositide 3‐kinase (PI3K)/Akt, thereby inhibiting survival pathways and promoting apoptosis of cancer cells. Moreover, berberine influences the expression of tumor suppressor genes, curtails cancer cell migration and invasion, and modulates the tumour microenvironment. Despite promising preclinical evidence, further research is essential to comprehensively elucidate its mechanisms of action and evaluate its safety and efficacy in clinical settings. In the present review, we have highlighted the pharmacokinetics, biosynthesis, and recent research work done pertaining to berberine's strong anticancer activity. We have also emphasised on the research being done on nanoformulations of berberine, which aim to improve its stability and bioavailability.


    • Book : 39(1)
    • Pub. Date : 2025
    • Page : pp.e70073
    • Keyword :
  • 2025

    Abstract

    Chronic obstructive pulmonary disease (COPD) is a pervasive and incapacitating respiratory condition, distinguished by airway inflammation and the remodeling of the lower respiratory tract. Central to its pathogenesis is an intricate inflammatory process, wherein macrophages exert significant regulatory functions, and High mobility group box 1 (HMGB1) emerges as a pivotal inflammatory mediator potentially driving COPD progression. This study explores the hypothesis that HMGB1, within macrophages, modulates COPD through inflammatory mechanisms, focusing on its influence on macrophage polarization. Our investigation uncovered that HMGB1 is upregulated in the context of COPD, associated with an enhanced proinflammatory M1 macrophage polarization induced by cigarette smoke. This polarization is linked to suppressed cell proliferation and induced apoptosis, indicative of HMGB1's role in the disease's inflammatory trajectory. The study further implicates HMGB1 in the activation of the Nuclear factor kappa‐B (NF‐κB) signaling pathway and chemokine signaling within macrophages, which are likely to amplify the inflammatory response characteristic of COPD. The findings underscore HMGB1's critical involvement in COPD pathogenesis, presenting it as a significant target for therapeutic intervention aimed at modulating macrophage polarization and inflammation.


    • Book : 49(1)
    • Pub. Date : 2025
    • Page : pp.79-91
    • Keyword :
  • 2025

    ABSTRACT

    In this paper, a novel single‐layer patch antenna is presented, designed to excite dual resonant modes for bandwidth expansion. By arranging these elements into an array, the mutual coupling between them is effectively suppressed by exploiting their inherent modes. This design strategy effectively suppresses mutual coupling in the antenna array without the need for additional decoupling structures. Instead, modifications in the physical placement of closely spaced antenna elements achieve high isolation. Within −10 dB of impedance bandwidth, an isolation greater than 25 dB is achieved by the array, with an antenna profile of 0.017 λ0. Both simulation and experimental results demonstrate a strong correlation, affirming the design's effectiveness. The antenna array is capable of operating within the n78 band from 3.34 to 3.48 GHz, characterized by advantages such as high radiation efficiency, high isolation, and a low profile.


    • Book : 67(1)
    • Pub. Date : 2025
    • Page : pp.e70071
    • Keyword :
  • 2025

    ABSTRACT

    In this study, scaffolds based on natural polymer gelatin A, blended with polyvinylpyrrolidone were crosslinked by genipin (0.5 and 1 wt%), in order to investigate their mechanical performance and potential for biomedical application. Semi‐solid extrusion (SSE) 3D printing technique was used, enabling in situ crosslinking of the blend during processing. Swelling test showed that the swelling ratio reduces with higher concentration of genipin due to an increased crosslinking. The FTIR analysis confirmed the crosslinking of scaffolds by genipin. DSC analysis and mechanical testing have shown improved thermal and mechanical properties. Morphological analysis of scaffolds by FESEM showed increased toughening of the material with the crosslinking. Tensile strength and microhardness showed a significant rise in scaffolds with the increase in genipin content, which was up to 93.8% and 125.3%, respectively. These findings were in accordance with morphological features present in samples. The biological effect of the scaffold matrix system was evaluated by qualitative and quantitative cytotoxicity assessment in vitro, demonstrating the absence of cytotoxicity in tested preparations in a direct test. The cytotoxicity index based on the metabolic activity of cells in an indirect test showed up to 20% reduction of viability compared with the control, confirming the absence of cytotoxicity, which was additionally verified by propidium iodine staining of the cells exposed to scaffolds. The presented gelatin‐based crosslinked scaffolds obtained by 3D printing represent good candidates for biomedical application and future research that includes further in vitro and in vivo analysis.


    • Book : 116(1)
    • Pub. Date : 2025
    • Page : pp.e23639
    • Keyword :
  • 2025

    Abstract

    Neuroblastomas are the most common solid tumors outside of the brain that originate from immature neural crest cells, accounting for about 10% of all pediatric malignancies. The treatment for neuroblastomas involves a multimodal schedule, including surgery, radiation, chemotherapy, and immunotherapy. All these modalities are limited by side effects that might be severe, poor prognosis, and a high risk of recurrence. In the quest for additional therapeutic approaches, phytochemicals have attracted attention owing to their reported antitumor properties, safety, and multimechanistic mode of action. Several studies have used plant‐derived bioactive compounds such as phenolics and flavonoids, suggesting modulation of biomolecules and signal transduction pathways involved in neuroblastoma. We reviewed the findings of recent preclinical and clinical studies demonstrating the effects of phytochemicals on neuroblastoma, shedding light on their molecular mechanism of action and potential therapeutic applications.


    • Book : 51(1)
    • Pub. Date : 2025
    • Page : pp.e2115
    • Keyword :
  • 2025

    ABSTRACT

    Background

    The prognostic significance of extranodal sites in stage IV diffuse large B‐cell lymphoma (DLBCL) remains uncertain, making it challenging to select appropriate treatment strategies for individual patients. In this study, we aimed to evaluate the influence of different extranodal sites on prognosis in young patients with stage IV DLBCL who achieved complete remission (CR) following initial chemo‐immunotherapy and to explore the potential of autologous hematopoietic stem cell transplantation (ASCT) as a consolidation treatment for specific patient subgroups.

    Methods

    We retrospectively reviewed data from 119 patients with DLBCL aged < 60 years who achieved CR after chemo‐immunotherapy between 2008 and 2020. Patient survival rates were analyzed in correlation with different extranodal sites using univariate and multivariate models. Additionally, we assessed the effect of ASCT on 5‐year progression‐free survival (PFS) and overall survival (OS) in patients with different extranodal sites involved.

    Study Design

    A retrospective bicenter study.

    Results

    Univariate analysis revealed a significant decrease in survival rates in patients with a Deauville score of 3 and those with extranodal DLBCL affecting the spleen, bone marrow, nasosinus, and liver. In multivariate analysis, only nasosinusal involvement remained a significant predictor of reduced OS. Patients with spleen involvement benefited significantly from ASCT in terms of 5‐year PFS and OS, whereas those with nasosinusal involvement did not demonstrate any survival advantage with ASCT.

    Conclusion

    Our findings highlight the influence of specific extranodal sites on the prognosis of patients with stage IV DLBCL. The data indicate a clear need for precise patient stratification based on extranodal involvement for more effective treatment planning. Notably, patients with spleen involvement appear to benefit from ASCT, suggesting that this strategy could be useful in this subgroup. Further prospective studies are needed to confirm and incorporate these findings into clinical practice.


    • Book : 14(1)
    • Pub. Date : 2025
    • Page : pp.e70565
    • Keyword :
  • 2025


    • Book : 158()
    • Pub. Date : 2025
    • Page : pp.109906
    • Keyword :
  • 2025

    Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive, malignant embryonal tumor with dismal long-term survival despite aggressive multimodal therapy. While this tumor typically presents in infancy or early childhood, there are published case reports of adult-onset ATRT. Making prognostic conclusions or therapeutic decisions for this older patient population remains challenging due to the paucity of these reports. A 25-year-old female with Down syndrome presented with dysphagia and facial droop and was found to have an avidly enhancing, cerebellopontine angle mass. Histology demonstrated sheets of rhabdoid cells with loss of INI1 expression, pathognomonic for ATRT. Further sequencing detected a frameshift SMARCB1 mutation and methylation profiling matched with high confidence to the MYC subclass of ATRT. The patient was treated with subtotal surgical resection and focal proton beam irradiation, followed by chemotherapy on a modified regimen due to concern for heightened risk of treatment-related toxicity. On most recent follow-up 22 months from diagnosis, the patient remains without evidence of disease. This report represents the first known case of ATRT in a young adult patient with Down syndrome, offering unique mechanistic insight into the tumorigenesis of ATRT. Further studies are needed to define an appropriate risk-adapted and standardized therapeutic approach for this patient population.


    • Book : 47(1)
    • Pub. Date : 2025
    • Page : pp.e52-e57
    • Keyword :